High-dose vitamin A supplementation administered with vaccinations after 6 months of age:Sex-differential adverse reactions and morbidity
| Autor: | Ibriama Balde, Carlito Balé, Linda Hornshøj, Peter Aaby, Christine Stabell Benn, Mathias Jul Jørgensen, Ane Bærent Fisker, Bo Martin Bibby |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Vitamin
Male Pediatrics medicine.medical_specialty Placebo Vaccines Attenuated 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Sex Factors 030225 pediatrics Injection site Medicine Humans Drug Interactions Guinea-Bissau 030212 general & internal medicine Vitamin A Intracranial pressure Vaccines General Veterinary General Immunology and Microbiology business.industry Public Health Environmental and Occupational Health Infant Vitamin A supplementation vaccinations sex-differential reactions mobidity 3. Good health Vaccination Infectious Diseases Home visits chemistry Vaccines Inactivated Relative risk Dietary Supplements Molecular Medicine Female Measles vaccine Morbidity business |
| Zdroj: | Fisker, A B, Bale, C, Jørgensen, M J, Balde, I, Hornshøj, L, Bibby, B M & Benn, C S 2013, ' High-dose vitamin A supplementation administered with vaccinations after 6 months of age : Sex-differential adverse reactions and morbidity ', The Vaccine Quarterly, vol. 31, no. 31, pp. 3191-3198 . https://doi.org/10.1016/j.vaccine.2013.04.072 Fisker, A B, Bale, C, Jørgensen, M J, Balde, I, Hornshøj, L, Bibby, B M, Aaby, P & Benn, C S 2013, ' High-dose vitamin A supplementation administered with vaccinations after 6 months of age : sex-differential adverse reactions and morbidity ', Vaccine, vol. 31, no. 31, pp. 3191-8 . https://doi.org/10.1016/j.vaccine.2013.04.072 |
| Popis: | Background:WHO recommends vitaminAsupplementation(VAS) at vaccinationcontacts after sixmonthsof age. The effect of this recommendation on mortality has not been evaluated.Methods: We tested the effect of VAS at vaccination contacts on mortality in a randomised trial in GuineaBissau.In a subgroup within this trial we studied adverse reactions to VAS and whether VAS modifiedknown adverse reactions to live and inactivated vaccines and general morbidity during the first monthafter supplementation overall and by sex. Children aged 6–17 months were randomised to VAS or placeboat the day of vaccination (day 0). We interviewed the caretaker, assessed the fontanel and measuredtemperature and local reaction at the injection site at home visits on day 1, 2, 3, 7, 14, 21, and 31.We defined systemic adverse reactions to inactivated and live vaccines as fever on day 1 and 2 and on4–14 respectively. Clinical symptoms associated with increased intracranial pressure (ICP) on day 1 wereconsidered possible adverse reactions to VAS.Results: In 1673 children VAS had no overall effect on clinical symptoms associated with increased ICP(Relative Risk(RR) = 1.07 (95%CI: 0.85–1.35)). However, VAS was associated with such clinical symptomsin boys RR = 1.38 (1.00–1.91)) but not in girls (p = 0.03 for interaction between VAS and sex). VAS had noeffect on fever after inactivated vaccines. VAS had no overall effect on fever after live vaccines (RR = 0.86(0.53–1.39)), but tended to reduce the prevalence of fever in boys (RR = 0.58 (0.30–1.14)), but not in girls(RR = 1.37 (0.66–2.84)) (p = 0.09 for interaction between VAS and sex). VAS was associated with increasedlocal reactions to measles vaccine in both sexes (RR = 3.65 (1.20–11.12)).Conclusion: Adverse reactions were rare, mild and transient and may notin their own right cause concern.However, VAS caused sex-differential adverse reactions and may have sex-differential effects on adversereactions to vaccines. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|